Some anti-NASH drugs target metabolic pathways involved in hepatic fat accumulation; these drugs include: FXR agonists, PPAR agonists, de novo fat synthesis inhibitors such as the pan acetylcarboxylase (ACC) inhibitor MK-4074 and analogues of fibroblast growth factor (FGF). The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.